open access

Vol 72, No 3-4 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22
Get Citation

Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis

Iwona Stelmach, Aleksandra Korzeniewska, Katarzyna Smejda, Iwona Jarosz, Włodzimierz Stelmach
Pneumonol Alergol Pol 2004;72(3-4):85-89.

open access

Vol 72, No 3-4 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22

Abstract

Inflammatory process contributes to progressive lung tissue damage in cystic fibrosis(CF). Cysteinyl leukotrienes have been found in the sputum of CF patients at concentrations sufficienttocausepotentbiologicaleffect. This study was designed to assess the effect of anti-inflammatory treatment with montelukast sodium in CF patients.
Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean±SD,54,6 ± 22,6 before and 62 ± 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 ± 23,0 before and 37,5 ± 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF.

Abstract

Inflammatory process contributes to progressive lung tissue damage in cystic fibrosis(CF). Cysteinyl leukotrienes have been found in the sputum of CF patients at concentrations sufficienttocausepotentbiologicaleffect. This study was designed to assess the effect of anti-inflammatory treatment with montelukast sodium in CF patients.
Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean±SD,54,6 ± 22,6 before and 62 ± 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 ± 23,0 before and 37,5 ± 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF.
Get Citation

Keywords

cystic fibrosis; inflammation; leukotrienes; montelukast

About this article
Title

Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis

Journal

Advances in Respiratory Medicine

Issue

Vol 72, No 3-4 (2004)

Pages

85-89

Published online

2008-02-18

Bibliographic record

Pneumonol Alergol Pol 2004;72(3-4):85-89.

Keywords

cystic fibrosis
inflammation
leukotrienes
montelukast

Authors

Iwona Stelmach
Aleksandra Korzeniewska
Katarzyna Smejda
Iwona Jarosz
Włodzimierz Stelmach

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl